Bluejay Diagnostics Files 8-K Report
Ticker: BJDX · Form: 8-K · Filed: 2025-08-15T00:00:00.000Z
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Bluejay Diagnostics filed an 8-K on 8/15/25 for 'Other Events' - details TBD.
AI Summary
On August 15, 2025, Bluejay Diagnostics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details regarding transactions, agreements, or material events were provided in the excerpt.
Why It Matters
This filing signals that Bluejay Diagnostics has reported a material event to the SEC, which could be significant for investors monitoring the company's activities.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' without immediate disclosed financial impact or significant operational changes.
Key Players & Entities
- Bluejay Diagnostics, Inc. (company) — Registrant
- August 15, 2025 (date) — Date of earliest event reported
FAQ
What specific 'Other Events' are being reported by Bluejay Diagnostics, Inc. in this 8-K filing?
The provided excerpt of the 8-K filing does not specify the details of the 'Other Events' being reported, only that this is the item of disclosure.
When was this 8-K report filed by Bluejay Diagnostics, Inc.?
The report was filed on August 15, 2025.
What is the principal executive office address for Bluejay Diagnostics, Inc.?
The address is 360 Massachusetts Avenue, Suite 203, Acton, MA 01720.
What is the telephone number for Bluejay Diagnostics, Inc.?
The telephone number is (844) 327-7078.
Under which section of the Securities Exchange Act of 1934 is this 8-K report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 486 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2025-08-15 17:27:51
Filing Documents
- ea0253600-8k_bluejay.htm (8-K) — 23KB
- image_001.jpg (GRAPHIC) — 14KB
- 0001213900-25-077600.txt ( ) — 220KB
- bjdx-20250815.xsd (EX-101.SCH) — 3KB
- bjdx-20250815_lab.xml (EX-101.LAB) — 33KB
- bjdx-20250815_pre.xml (EX-101.PRE) — 22KB
- ea0253600-8k_bluejay_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On August 15, 2025, the Board of Directors (the "Board") of Bluejay Diagnostics, Inc. unanimously approved the following Board and committee Chair appointments, effective immediately: (i) Donald R. Chase as Chairperson of the Board (succeeding Douglas C. Wurth); (ii) Mr. Wurth as Chairperson of the Nominating and Corporate Governance Committee of the Board (succeeding Fred S. Zeidman), and (iii) Mr. Zeidman as Chairperson of the Compensation Committee of the Board (succeeding Mr. Chase). Mr. Chase remains Chairperson of the Audit Committee of the Board, and each of the three standing Board committees remain comprised of Messrs. Chase, Wurth and Zeidman. The foregoing Chair appointments were made as part of the Board's periodic review and consideration of Board and committee governance assignments. Each of Messrs. Chase, Wurth and Zeidman have been determined by the Board to be independent under applicable Nasdaq listing rules, and to satisfy the independence criteria under Rule 10A-3 under the Securities Exchange Act of 1934, as amended. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Bluejay Diagnostics, Inc. By: /s/ Neil Dey Neil Dey President and Chief Executive Officer Date: August 15, 2025 2